Opdivo: Additional Ph II CheckMate -205 data

Data from 100 patients with classical Hodgkin’s lymphoma who previously received Adcetris brentuximab vedotin before and/or after autologous hematopoietic stem cell transplantation (HSCT) in cohort C of the open-label, international Phase II CheckMate -205

Read the full 346 word article

User Sign In